Nam Suk Sim

6PUBLICATIONS
72CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)NeurogeneticsPredictive and prognostic markersFood properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 06, 2026
Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma.

Kum-Hee Yun, Nam Suk Sim, Su-Jin Shin

|Oct 26, 2024
Somatic variant analysis of resected brain tissue in epilepsy surgery patients.

Maurits W C B Sanders, Bobby P C Koeleman, Eva H Brilstra

|Mar 08, 2024
A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.

Chang Gon Kim, Min Hee Hong, Dahee Kim

|Feb 28, 2023
Investigation of somatic mutation profiles and tumor evolution of primary oropharyngeal cancer and sequential lymph node metastases using multiregional whole-exome sequencing.

Nam Suk Sim, Su-Jin Shin, Inho Park

|May 18, 2022
Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma.

Chang Gon Kim, Nam Suk Sim, Jeong Eun Kim

|Jan 12, 2022
Efficacy of the Ketogenic Diet for Pediatric Epilepsy According to the Presence of Detectable Somatic mTOR Pathway Mutations in the Brain.

Ara Ko, Nam Suk Sim, Han Som Choi

Pageof 1

Frequent Collaborators

2 joint publications

Ara Ko

2 joint publications

Inkyung Jung

2 joint publications

Sun Young Rha

2 joint publications

Hyo Song Kim